Fulgent Genetics’ Post

Our recombinant chimeric #VlsE for #Borrelia #Burgdorferi is a highly antigenic biomarker thanks to the multi-epitope presence in the molecule. We suggest a potential use of this chimera in the IVD diagnostics of Lyme disease, in both USA and especially in Europe, where the heterogeneity of the immunodominant epitopes must be considered. 🔗https://shorturl.at/Vn1CE #VlsE #lyme #multiepitope #RecombinantProteins #GetREKOMended

MEDx recently showcased its innovative companion diagnostics solutions at the 2024 Medlab Asia & Asia Health in Thailand, one of Southeast Asia's influential medical events. At the event, MEDx presented a comprehensive range of advanced diagnostic solutions, including over 20 diagnostic kits. Highlighted products featured molecular platform-based PCR and NGS detection reagents, protein platform-based IHC detection reagents, and nucleic acid extraction reagents. These products meet diverse diagnostic needs and include CE-certified solutions for solid tumors (e.g., PD-L1, MSI, MMR, Claudin18.2, c-MET) and hematologic malignancies (e.g., BCR-ABL quantitative detection, MPN quadruple detection, blood tumor Ig/BCR rearrangement MRD detection), supporting companion diagnostics, drug guidance, and prognosis monitoring for precision medicine. #MedlabAsia #CompanionDiagnostics #PrecisionMedicine #MolecularDiagnostics #HealthcareInnovation #NGS #PCR #IHC #MedicalExhibition #CECertified #QimingPortfolio #QimingHealthcare

LucidQuest Views >>> How we helped a Top-10 BioPharma company enhance its strategic decision-making in the Sickle Cell Disease space. #Casestudies #casestudy Comment below! >>> lqventures.com

LucidQuest Views >>> How we helped a Top-10 BioPharma company enhance its strategic decision-making in the Sickle Cell Disease space. #Casestudies #casestudy Comment below! >>> lqventures.com

#News 🎉 April 17, Sanofi's frexalimab injection received implicit approval for two clinical trials in China for the treatment of adults with relapsing multiple sclerosis (RMS) and adults with non-relapsing secondary progressive multiple sclerosis (nrSPMS). The CD40–CD40L costimulatory pathway regulates adaptive and innate immune responses and has been implicated in the pathogenesis of multiple sclerosis. Frexalimab is a second-generation anti-CD40L monoclonal antibody being evaluated for the treatment of multiple sclerosis. 👉Check out our CD40/CD40L products: https://lnkd.in/gdxitXfR ☎ Fill in your demand and contact way! https://lnkd.in/gjxPUE88 #celllinedevelopment #cancertreatment #drugdiscovery #antibody

#precisionmedicine, Or #targetedtherapy plays very critical role in advanced cancers day after day. our blood test #guardant360 enable guideline recommended complete genomic testing in order to help match patients to these #targetedtherapy, also monitor a patient's response to treatment, to help doctors refine treatment even further, which have made a radical difference in improving outcomes for patients battling advanced cancers. Hikma Pharmaceuticals Guardant Health Guardant Health AMEA #worldcancerday #wcd2024 #closethecaregap #guardant360 #liquidbiopsy #precisionmedicine

A Breakthrough in Alzheimer’s Disease Diagnosis: Roche and Eli Lilly’s pTau217 Plasma Biomarker Test The FDA has given breakthrough status to a diagnostic test developed by Roche and Eli Lilly for Alzheimer's disease. The pTau217 plasma biomarker test aims to provide a reliable and efficient means of identifying the disease. It can deliver swift and accurate results, enabling earlier intervention and more proactive management strategies. The test holds promise in revolutionizing diagnosis and expediting patient recruitment for clinical trials. It offers a non-invasive and accessible alternative to current diagnostic methods. The collaboration between Roche and Eli Lilly represents a beacon of hope for individuals affected by Alzheimer's and their loved ones. The test could also lead to advancements in personalized treatment approaches. For more details please click the link! https://lnkd.in/dXFDNqYz #marketaccess #reimbursement #pricing #hta #heor #healtheconomics #medicaldevices #pharmaceutical

ELRIG UK Drug Discovery 2024 is only a week away!   Nicholas Clare, Malek Haddad, Haris Choudhery and CEO, Chris Kirton will be attending and ready to showcase our cutting-edge iPSC-derived disease models and screening services. Celine Gomez will also be in attendance and presenting our poster: iPSC-derived hepatocytes as a novel platform for modelling Metabolic dysfunction-Associated Steatotic Liver Disease (MASLD) in vitro. So, whether you are looking for efficacy screening services, looking to predict hepatic safety, or in need of an iPSC-derived disease model to study #MASLD, #A1ATD, UTC disorders, Wilson’s disease or PFIC2, we have you covered.   Swing by our booth, D24, and check out Poster (no. 219), to discuss how our #CRISPR-edited disease models and in vitro screening platforms can de-risk your therapeutic research.   #DrugDiscovery #iPSC #CRISPR #Biotech #ELRIGDD24 #hepatocytes #liver #liverdisease #DefiniGEN

Are you working in #pharma or #chemical development and assessing #DILI , Drug-Induced Liver Injury? Tomorrow we are hosting a webinar on our unique ToxProfiler assay for mechanistic toxicity testing that measures 7 different stress responses to generate a toxicological fingerprint of your compound. 👉 How is this applied for DILI? By simultaneously measuring 7 different stress responses, quantitative points of departure (PoDs) are used to construct a unique ToxProfiler fingerprint that when combined with pharmacokinetic data, identifies in vivo relevant toxicities such as drug-induced liver injury (DILI) In the webinar you can also learn how the assay: ✅ predict mitochondrial toxicity, ✅ Derive point-of-departures and human cMAX , ✅ identify MOA, ✅ rank compounds and ✅ be applied in early phases of safety assessment Check it out and register !

LucidQuest Strategic Insights (lqventures.com) >>> Gene&Cell Therapy >> Merck partners with small UK biotech to drug fibroblasts for fibrosis, I&I diseases: As Merck builds out its immunology research lab in London, it’s partnering with a local biotech startup that has remained relatively quiet since its seed round in 2021. The pharma giant said Tuesday morning it is pairing up with Cambridge, UK-based Mestag Therapeutics to find new targets for fibrosis and inflammatory disease treatments. Merck will deliver an upfront payment of undisclosed size to the nearly four-year-old Mestag, which is working on drugging fibroblasts. These cells are integral to the formation of connective tissue and also help communicate with immune cells and give them navigation orders. If all goes to plan, Mestag stands to gain as much as $1.9 billion from the yearslong partnership that the duo has inked. Mestag could deliver a “number of targets,” but the startup’s CEO, Susan Hill, declined to disclose how many to Endpoints News. Merck will be responsible for developing any drugs that arise from the pact. The move comes as Merck makes bold bets on the I&I field, dishing out $10.8 billion to buy Prometheus Biosciences last year and $700 million upfront to buy an early clinical-stage T cell engager from Curon Biopharmaceutical this summer. “We’re also very happy to work with a partner that is very actively and demonstrably building out inflammatory disease and autoimmune discovery capabilities,” Hill said in an interview. For Mestag, the money infusion gives runway to get closer to the clinic. It disclosed a $45 million seed round in 2021 from SV Health Investors, Johnson & Johnson Innovation, GV, Northpond Ventures and Forbion. It also worked on an inflammatory disease collaboration with J&J for undisclosed terms, but that tie-up is “completing” and coming to an end, Hill said. The three dozen-employee startup will likely begin fundraising a Series A in the first half of 2025 so it can get into the clinic with its first experimental drug about 15 months from now, Hill said. The company’s first program, MST-0300, is a bispecific antibody that is meant to agonize lymphotoxin beta receptors in solid tumors and co-engage fibroblast activation protein, or FAP. It aims to induce tertiary lymphoid structures, or TLS, in solid tumors to drum up an immune response to the cancer. “There’s an incredible amount of data in the literature now showing that patients that have TLS in their tumors do better on overall survival and PFS,” Hill said. Behind that project, Mestag has inflammatory and autoimmune programs, including checkpoint agonists that target myeloid biology rather than T cell biology that other hot I&I drug modalities are going after, the CEO said. For example, multiple drugmakers are attempting to turn CAR-T cell therapies and T cell engagers into I&I medicines. Hill said…